Dexamethasone and Pemetrexed

The combination of dexamethasone and pemetrexed is primarily used in cancer treatment, particularly for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. Dexamethasone is administered as a premedication to prevent pemetrexed-induced skin rash, which is a common side effect[1][2]. ## Administration and Dosing Pemetrexed (Alimta) is typically administered intravenously at a dose of 500 mg/m² on day 1 of treatment cycles[1][6]. For the dexamethasone component, several regimens have been studied: 1. Standard regimen: Dexamethasone 4 mg orally twice daily the day before, the day of, and the day after pemetrexed administration (total of 3 days)[2][7] 2. Alternative regimens: - Single-dose dexamethasone 20 mg prior to pemetrexed administration[2] - Low-dose dexamethasone 2 mg/day for 5 days beginning on the second day after pemetrexed administration[1][6] ## Mechanism and Purpose Pemetrexed is an antifolate antimetabolite that primarily inhibits thymidylate synthase (TS), resulting in decreased thymidine available for DNA synthesis[7]. It also inhibits dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT), which are key enzymes required for the de novo biosynthesis of thymidine and purine nucleotides[7]. Dexamethasone is administered specifically to reduce the incidence and severity of cutaneous reactions (rash) associated with pemetrexed therapy[7]. Studies have shown that premedication with dexamethasone significantly reduces the incidence of pemetrexed-induced rash from approximately 67.5% (without corticosteroids) to 14-16.7% (with corticosteroids)[1][6]. ## Clinical Applications The combination is used for: - Non-squamous non-small cell lung cancer (NSCLC), either in combination with cisplatin as initial treatment or as maintenance therapy - Malignant pleural mesothelioma, in combination with cisplatin - Recurrent metastatic disease following prior chemotherapy[5] ## Side Effects and Monitoring Common side effects of the pemetrexed component include: - Skin rash (significantly reduced with dexamethasone premedication) - Fatigue - Nausea - Bone marrow suppression - Renal toxicity Patients receiving this combination should also receive folic acid and vitamin B12 supplementation to reduce overall treatment-related toxicity[7]. The effectiveness of this combination therapy, particularly the role of dexamethasone in preventing pemetrexed-induced rash, has been demonstrated in multiple clinical trials and is now considered standard practice in the administration of pemetrexed-based chemotherapy regimens.